Relevant bibliographies by topics / Insulines / Journal articles

Journal articles on the topic 'Insulines'

To see the other types of publications on this topic, follow the link: Insulines.
Author: Grafiati
Published: 13 May 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Insulines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Faure, Sébastien. "Insulines." Actualités Pharmaceutiques 51, no. 512 (January 2012): 49–54. http://dx.doi.org/10.1016/s0515-3700(12)71130-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

de Klaver, P. A. G. "Nieuwe insulines en nieuwe toedieningswegen van insulines." Medisch-Farmaceutische Mededelingen 47, no. 7 (July 2009): 107–8. http://dx.doi.org/10.1007/bf03079996.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Battu, Valérie. "Les insulines." Actualités Pharmaceutiques 52, no. 530 (November 2013): 55–59. http://dx.doi.org/10.1016/j.actpha.2013.09.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fougere, Édouard. "Les insulines." Actualités Pharmaceutiques 60, no. 606 (May 2021): 55–57. http://dx.doi.org/10.1016/j.actpha.2021.03.021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Messaad, Djamel, Omar Outtas, and Pascal Demoly. "Hypersensibilité aux insulines." La Presse Médicale 33, no. 9 (May 2004): 631–38. http://dx.doi.org/10.1016/s0755-4982(04)98691-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Waton, J., and A. Barbaud. "Comment tester les insulines ?" Revue Française d'Allergologie 52, no. 3 (April 2012): 280. http://dx.doi.org/10.1016/j.reval.2012.02.082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Halimi, S., N. Wion, A. L. Coulon, and P. Y. Benhamou. "Les insulines, ultra-rapides, et techniques pour accélérer l’action des insulines rapides." Médecine des Maladies Métaboliques 8, no. 2 (April 2014): 125–32. http://dx.doi.org/10.1016/s1957-2557(14)70724-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

M, J. M. "Insulines : après Lantus®, U300." Revue Francophone des Laboratoires 2014, no. 460 (March 2014): 15. http://dx.doi.org/10.1016/s1773-035x(14)72385-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Halimi, S. "Avant-propos: Les insulines, demain." Médecine des Maladies Métaboliques 8, no. 2 (April 2014): 123. http://dx.doi.org/10.1016/s1957-2557(14)70723-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ekelmans, Nathalie. "Zorgen over preferentiebeleid (biosimilar) insulines." Nederlands Tijdschrift voor Diabetologie 19, no. 1 (March 2021): 18–21. http://dx.doi.org/10.1007/s12467-021-0615-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

SOLA, A., E. LARGER, J. MBEMBA, F. ELGRABLY, and G. SLAMA. "Les nouvelles insulines: intérêts et inconvénients." Réanimation 15, no. 6 (November 2006): 454–60. http://dx.doi.org/10.1016/j.reaurg.2006.09.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Boone, Emilie, Laura Boulan, Ditte S. Andersen, Nuria Romero, Pierre Léopold, and Julien Colombani. "Des insulines pour orchestrer la croissance." médecine/sciences 33, no. 6–7 (June 2017): 637–41. http://dx.doi.org/10.1051/medsci/20173306021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Chast, François. "Nouvelles insulines : innovations moléculaires, galéniques et biopharmaceutiques." Bulletin de l'Académie Nationale de Médecine 201, no. 7-9 (September 2017): 1255–68. http://dx.doi.org/10.1016/s0001-4079(19)30405-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Colas, L., G. Veyrac, A. Pipet, G. Gaillet, C. Bernier, and A. Magnan. "Une bien étrange hypersensibilité aux insulines humaines…" Revue Française d'Allergologie 59, no. 3 (April 2019): 276. http://dx.doi.org/10.1016/j.reval.2019.02.109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Raisin, Sophie, Sophie Pantalacci, and Pierre Léopold. "Les insulines des invertébrés sèment le trouble." médecine/sciences 18, no. 5 (May 2002): 610–15. http://dx.doi.org/10.1051/medsci/2002185610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Ghembaza, M. E. A. "Allergie aux insulines, à propos d’un cas." Annales d'Endocrinologie 75, no. 5-6 (October 2014): 402. http://dx.doi.org/10.1016/j.ando.2014.07.442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Renard, Éric. "La Suppléance Insulinique : nouvelles insulines, nouveaux procédés d'administration." Journal de la Société de Biologie 201, no. 2 (2007): 141–48. http://dx.doi.org/10.1051/jbio:2007017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Reix, N., F. Moreau, A. H. Spizzo, C. Canel, B. Catargi, S. Sigrist, and N. Jeandidier. "Les insulines intelligentes : une nouvelle forme de pancréas artificiel." Médecine des Maladies Métaboliques 8, no. 2 (April 2014): 141–46. http://dx.doi.org/10.1016/s1957-2557(14)70726-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Scheen, André J., and Pierre J. Lefèbvre. "L'épopée des insulines des années 1930 aux années 1980." Médecine des Maladies Métaboliques 15, no. 3 (June 2021): 3S25–3S31. http://dx.doi.org/10.1016/s1957-2557(21)00177-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Halimi, S. "La venue des insulines biosimilaires en France : Pour quoi faire ?" Médecine des Maladies Métaboliques 9, no. 3 (May 2015): 237–39. http://dx.doi.org/10.1016/s1957-2557(15)30067-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Chai, Weidong, Yangsong Wu, Guolian Li, Wenhong Cao, Zequan Yang, and Zhenqi Liu. "Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury." American Journal of Physiology-Endocrinology and Metabolism 294, no. 1 (January 2008): E183—E189. http://dx.doi.org/10.1152/ajpendo.00571.2007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Myocardial ischemia-reperfusion injury contributes significantly to morbidity and mortality in patients with diabetes. Insulin decreases myocardial infarct size in animals and the rate of apoptosis in cultured cells. Ischemia-reperfusion activates p38 mitogen-activated protein kinase (MAPK), which regulates cellular apoptosis. To examine whether p38 MAPK affects insulin's cardioprotection against ischemia-reperfusion injury, we studied overnight-fasted adult male rats by use of an in vivo rat model of myocardial ischemia-reperfusion. A euglycemic clamp (3 mU·min−1·kg−1) was begun either 10 min before ischemia (InsulinBI), 5 min before reperfusion (InsulinBR), or 30 min after the onset of reperfusion (InsulinAR), and continued until the end of the study. Compared with saline control, insulin decreased the infarct size in both InsulinBI ( P < 0.001) and InsulinBR ( P < 0.02) rats but not in InsulinAR rats. The ischemic area showed markedly increased phosphorylation of p38 MAPK compared with the nonischemic area in saline animals. Acute activation of p38 MAPK with anisomycin (2 mg/kg iv 10 min before ischemia) had no effect on infarct size in saline rats. However, it completely abolished insulin's protective effect in InsulinBI and InsulinBR rats. Activation of p38 MAPK by anisomycin was associated with marked and persistent elevation in IRS-1 serine phosphorylation. Treatment of animals with SB-239063, a potent and specific inhibitor of p38 MAPK, 10 min before reperfusion enabled insulin-mediated myocardial protection in InsulinAR rats. We conclude that insulin protects myocardium against ischemia-reperfusion injury when given prior to ischemia or reperfusion, and activation of p38 MAPK abolishes insulin's cardioprotective effect.
22

Boullu, S., J. Simeoni, S. Boivin, R. Sapin, F. Ortega, M. Pinget, and N. Jeandidier. "P019 - Évolution des anticorps anti-insuline (AAI) sous infusion intrapéritoneale (IP) d’insuline par pompe implantée (IPIP) en fonction des insulines utilisées." Annales d'Endocrinologie 66, no. 5 (October 2005): 413. http://dx.doi.org/10.1016/s0003-4266(05)81860-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Viard Gaudin, G., M. Baudrant-Boga, I. Debaty, S. Lablanche, and P. Y. Benhamou. "P085 Docteur, je pars à l’étranger, comment faire pour mes insulines ?" Diabetes & Metabolism 41 (March 2015): A54. http://dx.doi.org/10.1016/s1262-3636(15)30198-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Kastalli, S., S. El Ferjani, R. Sahnoun, G. Lakhoua, A. Zaiem, S. El Aidli, and R. Daghfous. "Allergie aux insulines avec tests cutanés positifs : à propos d’un cas." Revue Française d'Allergologie 55, no. 3 (April 2015): 246. http://dx.doi.org/10.1016/j.reval.2015.02.106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Amrouche, C., O. Berriche, I. Ksira, H. Sfar, E. Khadraoui, and H. Jamoussi. "Insulinothérapie chez le diabétique de type 2 : insulines conventionnelles ou analogues ?" Annales d'Endocrinologie 76, no. 4 (September 2015): 538. http://dx.doi.org/10.1016/j.ando.2015.07.803.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Monnier, Louis, Claude Colette, and David Owens. "Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée." Médecine des Maladies Métaboliques 15, no. 3 (June 2021): 3S32–3S52. http://dx.doi.org/10.1016/s1957-2557(21)00178-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Monnier, L., and C. Colette. "Insulines lentes aujourd’hui et demain : pour quels besoins non ou mal couverts ?" Médecine des Maladies Métaboliques 8, no. 2 (April 2014): 133–40. http://dx.doi.org/10.1016/s1957-2557(14)70725-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Maillard, Élisa, Séverine Sigrist, Laurent Meyer, and Nathalie Jeandidier. "Insulines intelligentes et pancréas bioartificiel dans le DT1 : acteurs de demain, vraiment?" Médecine des Maladies Métaboliques 15, no. 3 (June 2021): 3S65–3S75. http://dx.doi.org/10.1016/s1957-2557(21)00180-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

De Loynes, Anne, Gaetane Croux, Jacques Beltrand, Martine Postaire, Sylvie Jacquin, and Aurélie Guerin. "Évaluation des connaissances sur les insulines par les infirmières d’un hôpital universitaire pédiatrique." Le Pharmacien Hospitalier et Clinicien 54, no. 1 (March 2019): 99. http://dx.doi.org/10.1016/j.phclin.2018.10.043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Bottinelli, Charline, Laurent Fanton, Nathalie Cartiser, Jérôme Guitton, and Fabien Bévalot. "Identification et dosage des insulines en post-mortem : l’importance de multiplier les prélèvements." Toxicologie Analytique et Clinique 33, no. 3 (September 2021): S29—S30. http://dx.doi.org/10.1016/j.toxac.2021.06.032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Jamin, Christian. "Role of Estradiol, Progestins, Insulines and Adipocytokines in Breast Cancer Promotion in Post-Menopausal Women." Journal of Cancer Therapy 01, no. 01 (2010): 43–47. http://dx.doi.org/10.4236/jct.2010.11007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Colette, C., and L. Monnier. "Trouver de nouvelles insulines pour moduler leur profil d’action : pourquoi tout n’est-il pas possible ?" Médecine des Maladies Métaboliques 6, no. 1 (February 2012): 49–58. http://dx.doi.org/10.1016/s1957-2557(12)70355-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Kessouri, M., and S. Madani. "CA-121: Facteurs Prédictifs et explicatifs des modifications du poids après mise sous insulines analogues." Diabetes & Metabolism 42 (March 2016): A68. http://dx.doi.org/10.1016/s1262-3636(16)30253-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Faillie, J. L., and J. Bringer. "Le risque de cancer associé aux médicaments du diabète de type 2 (metformine, sulfonylurées et insulines)." Médecine des Maladies Métaboliques 8, no. 4 (September 2014): 365–71. http://dx.doi.org/10.1016/s1957-2557(14)70833-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Ounaissa, K., R. Rachdi, E. Khadhraoui, H. Abdesselem, O. Laajili, K. Ben Naceur, S. Zribi, I. Sebai, and C. Amrouche. "Évolution de l’équilibre glycémique chez les diabétiques de type 2 sous insulines conventionnelles et sous analogues." Annales d'Endocrinologie 81, no. 4 (September 2020): 428. http://dx.doi.org/10.1016/j.ando.2020.07.815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Faure, Guénaelle, Marion Desplanques, Patricia Dutrieux, Souraya Loubat, Sylvie Hendricx, and Pascale Guillain. "Bilan d’une démarche relative à la conservation et à l’administration des insulines : les limites de l’expertise pharmaceutique." Le Pharmacien Hospitalier et Clinicien 49, no. 4 (December 2014): 325. http://dx.doi.org/10.1016/j.phclin.2014.10.049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Rachdi, R., K. Ounaissa, O. Laajili, N. Souissi, H. Moalla, E. Bornaz, F. Boukhayatia, and C. Amrouche. "Évaluation du degré de satisfaction des patients diabétiques de type 2 sous insulines conventionnelles et sous analogues." Annales d'Endocrinologie 81, no. 4 (September 2020): 441. http://dx.doi.org/10.1016/j.ando.2020.07.853.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Leroy, Vincent, Marine Lazaro, Bastien Raymond, and Agnès Henry. "Évaluation des connaissances des personnels soignants sur les pratiques d’administration de l’insuline et impact de l’introduction des insulines à forte concentration." Recherche en soins infirmiers N° 134, no. 3 (2018): 44. http://dx.doi.org/10.3917/rsi.134.0044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Solignac, Marie. "Novo Nordisk obtient une AMM européenne pour les insulines Tresiba® et Ryzodeg® dans le traitement du diabète de l'adulte." Médecine des Maladies Métaboliques 7, no. 2 (March 2013): 192. http://dx.doi.org/10.1016/s1957-2557(13)70525-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Gaudier, Martin. "Profil pharmacodynamique de BioChaperone Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2." Diabetes & Metabolism 43, no. 2 (March 2017): A45. http://dx.doi.org/10.1016/s1262-3636(17)30230-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Megret, Claire. "BioChaperone Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline." Diabetes & Metabolism 43, no. 2 (March 2017): A115—A116. http://dx.doi.org/10.1016/s1262-3636(17)30441-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Bridel, M. P., C. Levy-Marchal, and D. Porquet. "Les auto-anticorps anti-insuline : marqueur prédictif de survenue de diabète insulino-dépendant ?" Immuno-analyse & Biologie Spécialisée 6, no. 1 (February 1991): 37–41. http://dx.doi.org/10.1016/s0923-2532(05)80360-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Chevenne, Didier. "Insuline (anticorps anti-insuline)." EMC - Biologie Médicale 1, no. 1 (January 2006): 1–3. http://dx.doi.org/10.1016/s2211-9698(06)76086-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Shestakova, Marina Vladimirovna, and Irina Vladimirovna Glinkina. "Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)." Diabetes mellitus 13, no. 1 (March 15, 2010): 88–90. http://dx.doi.org/10.14341/2072-0351-6022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms. 52 tumours were diagnosed in 45 (0.8%) patients on insulin glargine therapy and 48 tumors in 46 (0.9%) patients using other insulins(mostly NPX insulin). The incidence of breast cancer was equal (0.1%) in both groups (4 and 6 cases respectively). These data indicate thatthe use of insuline glargine does not increase the risk of malignancy, e.g. breast cancer.
45

&NA;. "Insulins." Reactions Weekly &NA;, no. 1198 (April 2008): 27. http://dx.doi.org/10.2165/00128415-200811980-00080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

&NA;. "Insulins." Reactions Weekly &NA;, no. 1205 (June 2008): 17. http://dx.doi.org/10.2165/00128415-200812050-00047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

&NA;. "Insulins." Reactions Weekly &NA;, no. 1218 (September 2008): 20. http://dx.doi.org/10.2165/00128415-200812180-00064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

&NA;. "Insulins." Reactions Weekly &NA;, no. 1322 (October 2010): 18. http://dx.doi.org/10.2165/00128415-201013220-00059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

&NA;. "Insulins." Reactions Weekly &NA;, no. 1283 (January 2010): 56. http://dx.doi.org/10.2165/00128415-201012830-00176.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

&NA;. "Insulins." Reactions Weekly &NA;, no. 1261 (July 2009): 17. http://dx.doi.org/10.2165/00128415-200912610-00056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Insulines' for other source types:
Dissertations / Theses Books

To the bibliography